ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

GSK Gsk Plc

1,708.60
3.40 (0.20%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  3.40 0.20% 1,708.60 1,708.60 1,708.80 1,713.00 1,699.40 1,701.60 11,522,668 16:29:59
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 14.27 70.34B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,705.20p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,719.80p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £70.34 billion. Gsk has a price to earnings ratio (PE ratio) of 14.27.

Gsk Share Discussion Threads

Showing 19001 to 19024 of 33075 messages
Chat Pages: Latest  771  770  769  768  767  766  765  764  763  762  761  760  Older
DateSubjectAuthorDiscuss
30/1/2019
13:31
Sector rotation starting to take place.
The pharmas should have a good run for a while.
GSK and AZN powering ahead.

fuji99
30/1/2019
12:42
If there is any CGT payable as a result of presumed sale, that represents value destruction.

A demerger has been intimated but debt is debt.

New drugs are the solution.

zicopele
30/1/2019
11:57
Presumably they believe that a breakup would be by a sale, rather than a share distribution. The proceeds used to pay off debt.
alphorn
30/1/2019
11:53
How is a breakup a solution to debt? Debt has to be repaid.

Solution to debt is drug discoveries and that may include reducing dividend.

Hopefully Tesaro will be successful as acquisition.

zicopele
30/1/2019
09:13
Tipped by Telegraph:

Questor: "Glaxo’s breakup is a neat solution to its debt problem, so it’s time to buy back in"

tradermichael
30/1/2019
08:49
Fantastic, they said 1 in 3 people will get shingles, massive market. I paid 130 pounds for a shingles vac.GSK double blockbuster on Shringlix I reckon.
montyhedge
30/1/2019
08:38
Glaxo has seen strong growth momentum in its three new products — Trelegy Ellipta, Shingrix and Juluca – so far this year - each could become a blockbuster
tradermichael
30/1/2019
08:32
Demand outstripping supply for shingles vac, what a great problem to have. Already blockbuster could we have double blockbuster coming years for that vaccine.
montyhedge
29/1/2019
18:00
Yes lessons were learnt,good bittersweet memories,no regrets easy come easy go,that's life!
abdullla
29/1/2019
16:41
Same here....I paid for a holiday on a company called eprime financial.

Lost on scoot.com and Marconi. Remember John Mayo?

zicopele
29/1/2019
16:39
Yeah, I made and lost a fortune on Scoot.
tradermichael
29/1/2019
16:21
Crikey...Energis is a name from the past.

Anyone remember the shill who used to shamelessly pump Sopheon?

Those companies went pop in 2001. Scoot.com.is another beauty.

zicopele
29/1/2019
16:04
Abdullla woz with TMF in the late sixties,these were the times of the disgraced Baltimore,Marconi and Energis all now are RIP!
abdullla
29/1/2019
15:40
Long since given up with TMF Their articles are anodyne and generic - its a shame as back in the early days they used to offer some insight and the tips actually did quite well. I did have a few conversations with one of the better authors too.
dr biotech
29/1/2019
14:56
Stupid article - the GSK network of local subsidiaries will ensure minimal impact of any loss of sales on the Continent for currently approved products.
alphorn
29/1/2019
13:59
TMF is run by shysters. One says buy on a share and his colleague advises sell.
zicopele
29/1/2019
13:17
A couple of snippets from TMF:

See the recent relation of the share price to results announcements. The price has fallen between 1% and 3.5% on three of the previous four results days in the past year, but has recovered quickly thereafter.


As far as Brexit,less than 30% of the companies’ revenues came from Europe in the last quarter, with the rest coming from the US and other international markets, helping to protect it from excessive exposure to a possibly-weaker UK or EU economy.

tradermichael
29/1/2019
12:59
Our next quarterly dividend soon is 23p, dividend on the doormat every 13 weeks, I love GSK, lol.
montyhedge
29/1/2019
12:54
Forward guidance not good.
zicopele
29/1/2019
12:52
They beat on earnings, beat on sales, investors always want more, lol.
montyhedge
29/1/2019
12:50
PFE is down in the premarket
zicopele
29/1/2019
11:49
Good figures and they beat analyst forecasts, just out from Pfzier bodes well for the sector.
montyhedge
29/1/2019
09:05
There will probably be a sector rotation and IMO the bio/pharmas turn has arrived as they lost a lot in just less than 2 weeks - Reference to GSK and AZN in particular.
This is following a strong run by oilers and miners in particular.
Defensive stocks will follow for a nice run.

fuji99
29/1/2019
08:50
Nice problem to have demand far outweighed supply.
montyhedge
Chat Pages: Latest  771  770  769  768  767  766  765  764  763  762  761  760  Older

Your Recent History

Delayed Upgrade Clock